$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

$tnxp Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000138713122008503 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.390M	$6.757M	$8.014M
YoY Change	35.52%	24.46%	48.13%
% of Gross Profit
Research & Development	$22.20M	$16.58M	$18.42M
YoY Change	69.71%	-8.57%	20.17%
% of Gross Profit
Depreciation & Amortization	$252.0K	$102.0K	$63.00K
YoY Change	2420.0%	3300.0%	530.0%
% of Gross Profit
Operating Expenses	$22.20M	$16.58M	$26.44M
YoY Change	19.78%	-8.57%	27.46%
Operating Profit	-$29.59M	-$23.34M	-$26.44M
YoY Change	59.65%	-0.96%
Interest Expense	$610.0K	$196.0K	$19.00K
YoY Change	8614.29%	2077.78%	-76.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$28.98M	-$23.14M	-$26.42M
YoY Change	56.42%	-1.75%	27.93%
Income Tax
% Of Pretax Income
Net Earnings	-$28.98M	-$23.14M	-$26.42M
YoY Change	56.42%	-1.75%	27.91%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.69	-$1.22	-$1.61
Diluted Earnings Per Share	-$0.69	-$1.22	-$1.619M
COMMON SHARES
Basic Shares Outstanding	43.06M shares	22.40M shares	16.45M shares
Diluted Shares Outstanding	41.94M shares	22.40M shares	16.45M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$140.0M	$145.5M	$140.4M
YoY Change	-23.5%	-12.21%	-14.47%
Cash & Equivalents	$140.0M	$145.5M	$140.4M
Short-Term Investments
Other Short-Term Assets	$11.16M	$46.27M	$12.55M
YoY Change	-7.85%	300.6%	39.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$151.1M	$191.7M	$153.0M
YoY Change	-22.53%	8.17%	-11.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$90.31M	$83.10M	$70.35M
YoY Change	367.89%	621.97%	603.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$360.0K	$379.0K	$379.0K
YoY Change	32.84%	42.48%	89.5%
Total Long-Term Assets	$91.51M	$84.42M	$70.73M
YoY Change	364.69%	609.63%	586.67%
TOTAL ASSETS
Total Short-Term Assets	$151.1M	$191.7M	$153.0M
Total Long-Term Assets	$91.51M	$84.42M	$70.73M
Total Assets	$242.6M	$276.2M	$223.7M
YoY Change	12.98%	45.99%	21.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.556M	$9.568M	$9.397M
YoY Change	-42.79%	180.92%	224.03%
Accrued Expenses	$8.784M	$6.341M	$5.957M
YoY Change	116.25%	35.64%	86.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.34M	$15.91M	$15.35M
YoY Change	10.93%	96.87%	155.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$382.0K	$474.0K	$405.0K
YoY Change	-27.92%	-19.8%	-32.5%
Total Long-Term Liabilities	$382.0K	$474.0K	$405.0K
YoY Change	-27.92%	-19.8%	-32.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.34M	$15.91M	$15.35M
Total Long-Term Liabilities	$382.0K	$474.0K	$405.0K
Total Liabilities	$13.72M	$16.38M	$15.76M
YoY Change	9.29%	88.92%	138.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$438.4M	-$409.4M	-$386.2M
YoY Change	32.73%
Common Stock	$667.4M	$637.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$228.9M	$228.3M	$208.0M
YoY Change
Total Liabilities & Shareholders Equity	$242.6M	$276.2M	$223.7M
YoY Change	12.98%	45.99%	21.92%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$28.98M	-$23.14M	-$26.42M
YoY Change	56.42%	-1.75%	27.91%
Depreciation, Depletion And Amortization	$252.0K	$102.0K	$63.00K
YoY Change	2420.0%	3300.0%	530.0%
Cash From Operating Activities	-$23.53M	-$21.17M	-$31.05M
YoY Change	81.79%	10.81%	47.42%
INVESTING ACTIVITIES
Capital Expenditures	-$8.820M	-$14.44M	-$20.22M
YoY Change	13.79%	913.97%	3864.12%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$8.820M	-$14.44M	-$20.22M
YoY Change	13.79%	913.97%	3864.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.625M	72.18M	13.06M
YoY Change	-112.18%	227.35%	-87.98%
NET CHANGE
Cash From Operating Activities	-23.53M	-21.17M	-31.05M
Cash From Investing Activities	-8.820M	-14.44M	-20.22M
Cash From Financing Activities	-4.625M	72.18M	13.06M
Net Change In Cash	-36.98M	36.57M	-38.20M
YoY Change	-314.2%	2307.31%	-143.84%
FREE CASH FLOW
Cash From Operating Activities	-$23.53M	-$21.17M	-$31.05M
Capital Expenditures	-$8.820M	-$14.44M	-$20.22M
Free Cash Flow	-$14.71M	-$6.732M	-$10.83M
YoY Change	183.25%	-61.93%	-47.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001430306
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	940000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	985000	usd
CY2021Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2021Q2	tnxp	Stock Issued During Period Value New Issues20 StockIssuedDuringPeriodValueNewIssues20		usd
	tnxp	Common Stock Issued To Acquire Research And Development CommonStockIssuedToAcquireResearchAndDevelopment		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409377000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145478000	usd
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	474000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	511000	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36019
	dei	Entity Registrant Name EntityRegistrantName	TONIX PHARMACEUTICALS HOLDING CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1434750
	dei	Entity Address Address Line1 EntityAddressAddressLine1	26 Main Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chatham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07928
	dei	City Area Code CityAreaCode	(862)
	dei	Local Phone Number LocalPhoneNumber	799-9155
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	TNXP
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43061066	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145478000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178660000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	31500000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14769000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10389000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	191747000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	189049000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83099000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50558000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	940000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	914000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	379000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	379000	usd
CY2022Q2	us-gaap	Assets Assets	276165000	usd
CY2021Q4	us-gaap	Assets Assets	240900000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9568000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13282000	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5830000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7945000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	511000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	489000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15909000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21716000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	474000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	467000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	16383000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	22183000	usd
CY2022Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31692024	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31692024	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15638274	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15638274	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	32000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	637770000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	578613000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409377000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359820000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-143000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-92000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	228282000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	218717000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	276165000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240900000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16579000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18133000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35001000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33460000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6757000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5429000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14771000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10838000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	23336000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	23562000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	49772000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	44298000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23336000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23562000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-49772000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44298000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.49
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22404371	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.49
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	196000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	215000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	92000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23140000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-23553000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-49557000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44206000	usd
CY2022Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	4255000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	4255000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27395000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23553000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53812000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44206000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.25
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.76
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.76
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22404371	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10483112	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10483112	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19462280	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19462280	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9843309	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9843309	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23140000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-23553000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-49557000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44206000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-51000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23165000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23561000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49608000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44215000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	218717000	usd
CY2022Q1	tnxp	Stock Issued During Period Value New Issues10 StockIssuedDuringPeriodValueNewIssues10	8488000	usd
CY2022Q1	tnxp	Issuance Of Commitment Shares Under Purchase Agreement IssuanceOfCommitmentSharesUnderPurchaseAgreement	4535000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	40000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26417000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	207957000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2620000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-26000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	176916000	usd
CY2021Q2	tnxp	Stock Issued During Period Value New Issues2 StockIssuedDuringPeriodValueNewIssues2	18702000	usd
CY2021Q2	tnxp	Issuance Of Commitment Shares Under Purchase Agreement IssuanceOfCommitmentSharesUnderPurchaseAgreement	3347000	usd
CY2021Q2	tnxp	Stock Issued During Period Value New Issues21 StockIssuedDuringPeriodValueNewIssues21	3000000	usd
CY2022Q2	tnxp	Stock Issued During Period Value New Issues11 StockIssuedDuringPeriodValueNewIssues11	42968000	usd
CY2022Q2	tnxp	Issuance Of Commitment Shares Under Purchase Agreement IssuanceOfCommitmentSharesUnderPurchaseAgreement	1964000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	4255000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2813000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23140000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	228282000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	87648000	usd
CY2021Q1	tnxp	Stock Issued During Period Value New Issues1 StockIssuedDuringPeriodValueNewIssues1	2000	usd
CY2021Q1	tnxp	Stock Issued During Period Value New Issues14 StockIssuedDuringPeriodValueNewIssues14	36904000	usd
CY2021Q1	tnxp	Stock Issued During Period Value New Issues15 StockIssuedDuringPeriodValueNewIssues15	64997000	usd
CY2021Q1	tnxp	Stock Issued During Period Value New Issues19 StockIssuedDuringPeriodValueNewIssues19	6779000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	28000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1212000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-20653000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2089000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-23553000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	180493000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-49557000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44206000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	165000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000	usd
	tnxp	Common Stock Issued To Acquire Research And Development CommonStockIssuedToAcquireResearchAndDevelopment	3000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5433000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3301000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4381000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	651000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1564000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1191000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	2000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-17000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2315000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-415000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52217000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40166000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34656000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1934000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34656000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1934000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	40000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	28000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	27245000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	57955000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	130729000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85240000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	130759000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1682000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	88651000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178900000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77308000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-49000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177218000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165959000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1950000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	4255000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_807_eus-gaap--NatureOfOperations_zt1laFe3P0dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_824_zXFLm1HKsmb2">BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tonix Pharmaceuticals Holding Corp., through its wholly owned subsidiary Tonix Pharmaceuticals, Inc. (“Tonix Sub”), is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. The therapeutics include small molecules and biologics and all drug product candidates are still in development and none are approved or marketed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The condensed consolidated financial statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Sub, Krele LLC, Tonix Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., Jenner LLC, Tonix R&D Center LLC, Tonix Pharma Holdings Limited and Tonix Pharma Limited (collectively hereafter referred to as the “Company” or “Tonix”). All intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses from operations and negative cash flows from operating activities. At June 30, 2022, the Company had working capital of approximately $<span id="xdx_909_ecustom--WorkingCapital_iI_pn3d_dm_c20220630_z4saVO3KWC32" title="Working capital">144.3 million</span>, which excludes restricted cash of $<span id="xdx_90E_eus-gaap--RestrictedCashCurrent_iI_pn3d_dm_c20220630_zpebXo1HelD">31.5 million</span>. At June 30, 2022, the Company had an accumulated deficit of approximately $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20220630_zUvYYdidKUv1" title="Accumulated deficit::XDX::-409377"><span style="-sec-ix-hidden: xdx2ixbrl0607">409.4 million</span></span>. The Company held cash and cash equivalents of approximately $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dxL_c20220630_zc6jHSzh0654" title="Cash and cash equivalents::XDX::145478"><span style="-sec-ix-hidden: xdx2ixbrl0609">145.5 million</span></span> as of June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that its cash resources at June 30, 2022, and the gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3d_dm_c20220701__20220808__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1i0KoBwnq9l" title="Proceeds from equity offerings">18.9 million</span>, that it raised from equity offerings subsequent to the end of the second quarter of 2022 (See Note 19), will meet its operating and capital expenditure requirements into the second quarter of 2023, but not beyond.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company continues to face significant challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to changes it may make in its research and development spending plans. The Company has the ability to obtain additional funding through public and private financing and collaborative arrangements with strategic partners to increase the funds available to fund operations. However, the Company may not be able to raise capital on terms acceptable to the Company. Without additional funds, it may be forced to delay, scale back or eliminate some of its research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue operations. If any of these events occurs, our ability to achieve our development and commercialization goals would be adversely affected. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
CY2022Q2	tnxp	Working Capital WorkingCapital	144300000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	31500000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zslcXrmAjSZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Risks and uncertainties</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s primary efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated revenues, and there is no assurance that if its products are approved for sale, that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. Moreover, the extent to which COVID-19 impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zfvuOCKJV0N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the assumptions used in the fair value of stock-based compensation and other equity instruments, and the percent of completion of research and development contracts.</span></p>
CY2022Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	120600000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	120400000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	31500000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	240000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	240000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145478000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165719000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	31500000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	240000	usd
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	240000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177218000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165959000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	102000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	165000	usd
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9994519	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	800665	shares
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	83664000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50958000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	565000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	400000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83099000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50558000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	tnxp	Minimum Bid Requirement Per Share MinimumBidRequirementPerShare	1.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	805762	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	78.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1695608	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	26821	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	381.16
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2474549	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.54
	tnxp	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P9Y2M23D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	469600	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	83.90
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y14D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.25
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.45
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	985000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0167	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0305	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0080	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0163	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2032	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3322	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2440	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3774	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	19970	shares
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	275000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	409000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	154000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	159000	usd
CY2022Q2	tnxp	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	11000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1008000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	309000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	314000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M26D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M17D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0231	pure
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0136	pure
CY2022Q2	us-gaap	Other Commitment OtherCommitment	62500000	usd

Files In Submission

Name	View Source	Status
tnxp-20220630_cal.xml	Edgar Link	unprocessable
0001387131-22-008503-index-headers.html	Edgar Link	pending
0001387131-22-008503-index.html	Edgar Link	pending
0001387131-22-008503.txt	Edgar Link	pending
0001387131-22-008503-xbrl.zip	Edgar Link	pending
ex31-01.htm	Edgar Link	pending
ex31-02.htm	Edgar Link	pending
ex32-01.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tnxp-10q_063022.htm	Edgar Link	pending
tnxp-20220630.xsd	Edgar Link	pending
tnxp-10q_063022_htm.xml	Edgar Link	completed
tnxp-20220630_def.xml	Edgar Link	unprocessable
tnxp-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
tnxp-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2022 Q3 Form 10-Q Financial Statement

#000138713122008503 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2022 Q3 Form 10-Q Financial Statement

#000138713122008503 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp